News

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...
A new study published in Nanotechnology offers new hope for less harmful breast cancer therapy by combining two powerful, non ...
Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...
Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4 Itovebi is the first PI3K-targeted therapy to ...